PHARVAT

Platform for the Harmonization of Vaccine Adjuvant Testing

Coordinatore	STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER    more  Organization address address: LANGE KLEIWEG 161 city: RIJSWIJK ZH postcode: 2288 GJ contact info Titolo: Dr. Nome: Alan William Cognome: Thomas Email: send email Telefono: +31 15 284 2538 Fax: +31 15 284 3986
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	334˙018 €
EC contributo	300˙000 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-B
Funding Scheme	CSA-SA
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-11-01   -   2011-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER  Organization address address: LANGE KLEIWEG 161 city: RIJSWIJK ZH postcode: 2288 GJ contact info Titolo: Dr. Nome: Alan William Cognome: Thomas Email: send email Telefono: +31 15 284 2538 Fax: +31 15 284 3986	NL (RIJSWIJK ZH)	coordinator	90˙000.00
2	EUROPEAN VACCINE INITIATIVE - EEIG  Organization address address: IM NEUERHEIMER FELD 307 city: Heidelberg postcode: 69120 contact info Titolo: Dr. Nome: Odile Cognome: Leroy Email: send email Telefono: +45 20785437 Fax: +45 46462123	DE (Heidelberg)	participant	110˙000.00
3	WORLD HEALTH ORGANIZATION.  Organization address address: Avenue Appia 20 city: GENEVE postcode: 1211 contact info Titolo: Dr. Nome: Martin Cognome: Friede Email: send email Telefono: +41 22 791 4398 Fax: + 41 22 791 4860	CH (GENEVE)	participant	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Adjuvants are critical to the quality and magnitude of immune responses generated by PRD vaccines. However, vaccine development is hampered by lack of access to appropriate adjuvants. This is partly because adjuvants are developed in many organizations, with individual models and protocols that have been established independently. The resulting data on adjuvants are only rarely directly comparable and exploitable in other vaccine studies. The project objective is to determine the laboratory tests that can be used to harmonize pre-clinical determination of vaccine adjuvant activity and safety throughout Europe, including new-member countries, and in the developing world, based on an in-depth survey and analysis of best practice employed by industry and other stakeholders in adjuvant R&D. A database of survey results will be analysed by experts and used to establish the tests that are considered most useful by stakeholders to characterize adjuvant activity and safety. Dissemination of results will occur through a workshop organized with WHO for stakeholders (including key international organizations representatives), publications and websites. The tests will allow the activities of adjuvants to be compared directly and will therefore contribute a major advantage in the selection of adjuvants to be included in PRD vaccine development programmes.'

Introduzione (Teaser)

Additives or adjuvants that stimulate the immune system to make antibodies are critical to the production of effective vaccines. An EU-funded project, aims to optimise vaccination development through the harmonisation of adjuvant testing.